M&A/corporate and commercial
John Pitfield, partner at Choate, Hall & Stewart, focuses on counselling private equity and growth equity clients through navigating transactions involving mergers and acquisitions and private debt and equity offerings. Pitfield focuses on the health services, life sciences, media and telecoms industries, with experience representing clients from non-US jurisdictions.
Legal 500 Editorial commentary
- Profile
Accolades
Boston Elite
Profile
Position
John Pitfield, co-chair of Choate’s Business & Technology Group, helps private equity and growth equity clients to maximize the value of their transactions and strategic initiatives. John excels in leading teams in mergers and acquisitions and public and private debt and equity offerings, bringing a unique business judgment to these matters. He regularly advises public companies on a range of disclosure, governance, and board level matters. Additionally, John has years of experience working with Canadian companies on a wide range of matters. A gifted collaborator, John utilizes Choate’s superior resources and expertise in the areas of intellectual property and healthcare to provide exceptional service to clients in the life sciences and health services industries.
John’s clients include a range of investors and operating companies – particularly in the health services, life sciences, and technology, media, and telecom sectors – including Bain Capital, Candescent Partners, Summit Partners, Haemonetics, Pegasystems, and Forrester Research.
Education
University of Toronto Law School
LLB, 1997
Queen’s University
BA, 1994, first class distinction
Content supplied by Choate, Hall & Stewart
Key clients
- Ambler Brook Bain Capital Life Sciences BioNTEch SE Candescent Partners Cogito Corporation ENT Partners Forrester Research Inc Haemonetics Corporation Kadant Inc LeMaitre Vascular Pegasystems Inc PTC Inc Samsara BioCapital
Work highlights
Represented Bain Capital Life Sciences in $120 million growth equity financing of Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on discovery of innovative therapeutics for musculoskeletal diseases.
Represented LeMaitre Vascular, Inc. in connection with issuance of $150 million of 2.5% convertible senior notes. Additionally advised LeMaitre on a purchase agreement and indenture with US Bank National Association.